NCT06321705Available
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
Expanded Access, Open-Label, Safety Extension Study for Patients That Have Completed Parent Study CS1-003 and Who Are Judged by the Investigator to Benefit From Continued CS1 Treatment
Cereno Scientific ABClinicalTrials.govdrug
Study focus
- Disease/Condition
- Pulmonary Arterial Hypertension
- Drug/Device/Intervention
- CS1
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Cereno Scientific AB
- Location
- Gothenburg, Sweden
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Summary
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study
 is to evaluate long-term safety and tolerability of continued treatment with CS1.
ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06321705
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06321705 through Pure Global AI's free database. This phase not specified trial is sponsored by Cereno Scientific AB and is currently Available. The study focuses on Pulmonary Arterial Hypertension.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.